Purpose-built for targeted NGS



Gene Fusions and Translocations

Gene fusions can occur as a result of chromosomal inversions, interstitial deletions, or translocations in the genome. Gene fusions can drive cancer development and progression, making them important therapeutic targets. Archer technology is purpose-built for accurate, powerful and scalable gene fusion detection with next generation sequencing.

Detected in the following assays:

Archer FusionPlex
RNA assays

Copy number variations (CNVs)

Copy number variation (CNV) is a common form of structural genomic aberration in which large regions of the genome are deleted or duplicated. Constitutional and somatic CNVs are associated with a wide variety of cancers and represents and important area of research. Archer technology enables highly-multiplexed, quantitative assessment of genomic regions through next generation sequencing

Detected in the following assays:

Archer VariantPlex
DNA assays

Insertions/Deletions (indels)

Insertions and deletions (indels) are mutations of the genome resulting from the omission or addition of nucleotides into a sequence of DNA. Indels can alter amino acid coding sequence and cause detrimental cellular effects. Archer technology is uniquely suited for indel detection due to novel chemistry and powerful next generation sequencing analysis.


Single Nucleotide Variants/Polymorphisms (SNVs, SNPs)

Point mutations, single nucleotide variants (SNV) or single base substitutions of the genome can have various implications on cellular function, and can cause or lead to diseases of the genome – like cancer. Archer technology enables the precise targeting of the genome for nucleotide-level detection of point mutations with next generation sequencing.


RNA Gene Expression

Gene expression is a measure of functional RNA that can provide critical insights into cellular origin and regulation. The molecular signatures gathered from RNA abundance can assist in classification of tumor types. The quantitative nature of Archer technology allows for measuring relative RNA abundance so researchers can get more information from next generation sequencing.

Detected in the following assays:

Archer FusionPlex
RNA assays

Unrivaled cancer mutation detection by sequencing

Archer: A Culture of NGS Innovation

  • Alk, Ret, Ros1 v2 Panel

    Detect and identify fusions and mutations of human ALK, RET and ROS1 genes, including mutations involved in crizotinib resistance.

    Heme Panel

    Find fusions of 20 genes associated with hematological malignancies without knowing fusion partners or breakpoints.

    Sarcoma Panel

    Locate and characterize fusion partners of 26 genes associated with these soft tissue cancers using this NGS-based assay.

  • NTRK Panel

    Detect and characterize neurotrophic tyrosine kinase (NTRK1, NTRK2 and NTRK3) gene fusions without knowing fusion partners or breakpoints.

    FGFR Panel

    Find fibroblast growth factor receptor (FGFR1, FGFR2 and FGFR3) gene fusions and other mutations using this NGS-based assay.

    Custom Panel

    Bundle your preferred genes and exons with our simple lyophilized workflow, fusion detection technology and comprehensive analysis pipeline.

Get a quote

Subscribe to stay in the loop

How to contact us


2477 55th Street, Suite 202

Boulder, CO 80301


Phone: (877) 771 1093

Phone: (303) 357 9001

All content © 2016 ArcherDX, Inc.